Table 2.
Persistent and new HPV infections and resultant CIN2+ at the post-treatment study visit: time to detection of infection.
| # of infections |
% and 95%CI resulting in CIN2+ | Time between treatment and post-treatment visits (years) | ||
|---|---|---|---|---|
| Women with recurrent disease | Women with no recurrent disease | |||
| Persistent infections1 | ||||
| HPV16 | 8 | 37.5% (8.5% to 75.5%); (n=3) | 6, 6, 8 | 1, 3, 4, 4, 8 |
| HPV18 | 2 | 50.0% (1.3% to 98.7%); (n=1) | 3 | 8 |
| Other carcinogenic HPV | 8 | 25.0% (3.2% to 65.1%); (n=2) | 5, 8 | 1, 2, 3, 4, 7, 8 |
| New Infections2 | ||||
| HPV16 | 2 | 0% (n=0) | N/A | 7,8 |
| HPV18 | 3 | 0% (n=0) | N/A | 7, 8, 8 |
| Other carcinogenic HPV | 13 | 0% (n=0) | N/A | 4, 5, 5, 5, 5, 7, 7, 7, 7, 7, 8, 8, 8 |
1
Persistent infections were defined as type-specific HPV infections present during any of the pre-treatment study visits and at the post-treatment visit.
2
Women were at risk for developing a new infection if the HPV type in question was not present at any visit prior to follow-up was subsequently present at the post-treatment visit.